Under stress conditions, pro-survival and pro-death processes are concomitantly activated and the final outcome depends on the complex crosstalk between these pathways. In most cases, autophagy functions as an early-induced cytoprotective response, favoring stress adaptation by removing damaged subcellular constituents. Moreover, several lines of evidence suggest that autophagy inactivation by the apoptotic machinery is a crucial event for cell death execution. Here we show that apoptotic stimuli induce a rapid decrease in the level of the autophagic factor Activating Molecule in Beclin1-Regulated Autophagy (Ambra1). Ambra1 degradation is prevented by concomitant inhibition of caspases and calpains. By both in vitro and in vivo approaches, we demonstrate that caspases are responsible for Ambra1 cleavage at the D482 site, whereas calpains are involved in complete Ambra1 degradation. Finally, we show that Ambra1 levels are critical for the rate of apoptosis induction. RNA interference-mediated Ambra1 downregulation further sensitizes cells to apoptotic stimuli, while Ambra1 overexpression and, more efficiently, a caspase non-cleavable mutant counteract cell death by prolonging autophagy induction. We conclude that Ambra1 is an important target of apoptotic proteases resulting in the dismantling of the autophagic machinery and the accomplishment of the cell death program.
1
In most cases, autophagy functions as a cytoprotective mechanism, favoring stress adaptation that avoids cell death. However, several reports also suggest that autophagy contributes to cell death execution when apoptotic signaling is compromised. 4, 5 Although a physiological role of autophagy in cell death remains a matter for debate, there is evidence that autophagy may favour cell death by the selective removal of survival factors or by prolonged removal of cellular constituents, this resulting in the efficient demise of the cell. [6] [7] [8] [9] Besides the pro-survival and pro-death roles of autophagy, what it is now well established is the existence of a complex regulatory interplay between autophagy and apoptosis. There is evidence to indicate that these processes share common regulatory factors. 10 For example, Bcl-2 and Bcl-X L , two wellcharacterized anti-apoptotic proteins, are able to bind Beclin1, a core protein of the autophagy-inducing complex, and inhibit autophagy. [11] [12] [13] It has been further suggested that the tumor suppressor and apoptosis inducer p53 has a positive role in cell survival in response to stress, stimulating antioxidant pathways and, more importantly, autophagy. 11 The crosstalk between autophagy and apoptosis is further highlighted by data showing mutual regulation of these pathways through modification of each others' activity. On the one hand, it has been demonstrated that inhibiting the cleavage of several crucial autophagy-related proteins by apoptotic executioner proteases favors the autophagy pro-survival functions and counteracts cell death. [14] [15] [16] [17] However, Hou et al. 18 recently demonstrated the autophagic degradation of a subunit of the active caspase-8 enzyme during TNF-related apoptosisinducing ligand-induced autophagy, keeping the apoptotic response at bay. These results support the existence of crossregulatory mechanisms between both cell fate-determining processes, so that only one process can prevail.
Ambra1 (Activating Molecule in Beclin1-Regulated Autophagy) is an important regulator of the autophagic process. [19] [20] [21] Ambra1 promotes Beclin1 interaction with its target lipid kinase Vps34/PI3KC3 (phosphatidylinositol-3-OH kinase) to assemble a class III PI3KC3 complex, thus mediating the initial steps of autophagosome formation. 19 Proautophagic activity of Ambra1 is negatively regulated by the interaction to the dynein complex on cytoskeleton and by direct association with Bcl-2 on the mitochondrial outer membrane. 20, 21 Functional deficiency of Ambra1 in mice causes defects in the developing nervous system and embryonic death both associated with autophagy impairment, increased proliferation and a large number of supernumerary apoptotic cells. 19, 22 In particular, the latter aspect of this multifaceted phenotype prompted us to investigate the role of Ambra1 during apoptosis. We found that Ambra1 degradation is an early event during apoptosis and occurs in a caspase-and calpain-dependent manner. Ambra1 cleavage contributes to the onset of apoptosis, as the expression of a non-cleavable Ambra1 mutant partially prevents apoptosis execution by prolonging the pro-survival function of autophagy.
Results
Ambra1 is degraded during apoptosis execution. Cleavage of specific pro-autophagic factors by apoptotic proteases has been proposed as one of the mechanisms responsible for the inhibition of pro-survival autophagy. [14] [15] [16] [17] In light of these findings, and as an increased number of apoptotic cells could be observed in Ambra1-deficient mice, 19 we decided to study the involvement of the autophagic protein Ambra1 in apoptosis execution.
First, we analyzed Ambra1 levels following apoptosis induction. Human fibroblast 2FTGH (2F) cells were treated with staurosporine for 2, 4, 6 and 8 h, and Ambra1 expression levels were evaluated by western blot analysis. A significant decrease in the endogenous protein level of Ambra1 was observed starting from 4 h of staurosporine treatment ( Figure 1a) . Interestingly, Ambra1 reduction occurred concomitantly with caspase activation as monitored by poly (ADP-ribose)polymerase (PARP) cleavage (Figure 1a) . We also performed a dose-response Ambra1 expression analysis by treating 2F cells for 8 h with decreasing concentrations of staurosporine. Results reported in Figure 1b show a dosedependent decrease of Ambra1 protein correlating with the rate of caspase activation, as indicated by PARP cleavage (Figure 1b) , and the levels of cell death analyzed both by DNA fragmentation (data not shown) and by colony-formation assay (Figure 1c ). To exclude that Ambra1 protein downregulation during apoptosis was the result of transcriptional modulation, its mRNA levels were determined by quantitative RT-PCR (qRT-PCR). As shown in Supplementary Figure  S1a , no modulation of Ambra1 gene expression was observed 8 h after cell death induction. Then, we evaluated the levels of Ambra1 protein in other cell lines, such as A375, HeLa and Jurkat cells following cell death induction. As reported in Supplementary Figure S1 (b, c and d, respectively), Ambra1 protein downregulation is a common event during apoptosis execution.
To verify whether the observed Ambra1 cleavage was limited to the staurosporine-induced intrinsic apoptotic pathway or occurred also during death receptor-induced extrinsic apoptotic pathway, we stimulated Jurkat cells using TNFa þ CHX and evaluated the levels of Ambra1 protein. As reported in Figure 1d , Ambra1 protein was cleaved also under this experimental condition, thus indicating that its decrease is a general event occurring during apoptosis execution.
We then verified whether staurosporine treatment affected the levels of other autophagic proteins, such as ATG5, the Ambra1-interacting proteins Beclin1 and Vps34, previously described as being cleaved during apoptosis. 16, 17 Neither changes in the total levels of Atg5, Beclin1 and Vps34 nor the appearance of their cleaved fragments were observed during staurosporine-induced cell death, suggesting that Ambra1 is a preferential target of apoptosis-induced proteolysis in the 2F cell system (Figure 1a) . Interestingly, Beclin1 decrease was observed in Jurkat cells stimulated with both staurosporine or TNFa þ CHX, suggesting that its cleavage could be restricted to specific cell types (Supplementary Figure S1d and Figure 1d respectively).
To address the biological relevance of Ambra1 protein downregulation during apoptosis execution, freshly isolated mouse thymocytes were stimulated 5 h with Dexamethasone or 8 h with anti-CD95 agonistic antibody and Ambra1 and Beclin1 protein levels together with PARP cleavage were monitored. As shown in Figure 1e and Supplementary Figure S1e, both Ambra1 and Beclin1 were degraded during apoptosis execution.
During apoptosis, both calpains and caspases are activated, then being required for cell demise. 23 To verify whether Ambra1 is a target of these proteases during apoptotic execution, 2F cells were incubated for 4 or 6 h with staurosporine in the presence of calpain (CI) or caspase (z-VAD-fmk) inhibitors, either singly or in combination. Figure 1f , shows that the staurosporine-mediated Ambra1 decrease was completely prevented only when the two inhibitors were used in combination, suggesting that both caspases and calpains are involved in Ambra1 degradation.
Caspases involvement in Ambra1 degradation prompted us to investigate the presence of Ambra1 cleavage products during apoptosis. In Ambra1 overexpressing 2F cells, staurosporine treatment led to the appearance of specific N-terminal (B60 kDa ¼ Ambra1 plus myc-tag) and C-terminal (B100 kDa) cleavage products (Figures 2a and b , respectively). The kinetics of Ambra1 cleavage were similar to those of PARP (Figure 2a , bottom panel), confirming that Ambra1 cleavage occurred simultaneously with caspase activation. Staurosporine-mediated Ambra1 cleavage was inhibited by the caspase inhibitor z-VAD-fmk (Figure 2c ). Moreover, a partial inhibition was also observed using a calpain inhibitor Ambra1 degradation during apoptosis V Pagliarini et al (Figure 2d ), suggesting a contribution of both types of proteases in Ambra1 cleavage during apoptosis. Interestingly, Ambra1 fragments were not detected under staurosporine treatment at endogenous expression levels (data not shown), this possibly due to their low abundance or short half-life.
Apoptosis-mediated degradation of Ambra1 was not restricted to staurosporine treatment, as we also observed Ambra1 cleavage products using other pro-apoptotic stimuli, such as fenretinide, thapsigargin, tunicamycin and etoposide ( Figure 2e ). On the basis of these results, we conclude that Ambra1 is a target of proteolytic processing during apoptosis and propose that both calpains and caspases are involved in this cleavage event.
Modulation of Ambra1 expression affects cell susceptibility to apoptosis. To determine the role of Ambra1 protein degradation during apoptosis execution, we decided to evaluate the survival response of 2F cell line to cell death stimuli following Ambra1 downregulation. To this end, 2F cells were transfected with two Ambra1-specific siRNA oligonucleotides (siAmbra no. 1 and siAmbra no. 2, Figure 3a Collectively, these results indicate that Ambra1 functions as a pro-survival factor during apoptosis induction, thus supporting a role of Ambra1 degradation during cell death execution. identify the specific caspase(s) responsible for Ambra1 cleavage, we performed an in vitro caspase-cleavage assay. To this end, in vitro translated 35 S-labelled Ambra1 was subjected to cleavage by recombinant active caspase-3, -6, -7 and -8. As shown in Figure 5a and Supplementary Figure S4 , all caspases tested were able to cleave Ambra1 with high efficiency, generating several different cleavage products. Two fragments of B100 and B50 kDa, present in all digestions, likely represent the fragments detected in apoptotic cells (see Figure 2) . SitePrediction in silico analysis 24 of the Ambra1 protein sequence revealed several putative caspase recognition sites (Supplementary Table. 1). Taking into account the high preference for certain cleavage sites and the predicted size of the generated fragments, we have focused our research on the TESD 482 G site. To verify whether caspase cleavage indeed occurred at TESD 482 G, we generated an Ambra1 mutant carrying a single-point mutation (D 482 -A) in order to disrupt the predicted putative caspase cleavage site. As shown in Figure 5b , D 482 to A substitution completely abrogated the generation of both the 100-and 50-kDa Ambra1 fragments by caspase-6, -7 and -8, as compared with Ambra1 wild type (WT). By contrast, mutation of D 482 apparently did not prevent cleavage by caspase-3. However, direct comparison of the caspase-3-cleavage pattern of Ambra1
WT and Ambra1 D482A revealed that the fragments obtained with the Ambra1 mutant have a molecular weight which is slightly different when compared with the WT protein, possibly due to alternative cleavage sites being recognized by the caspase 3 when the D482 is mutated (Figure 5c ). We also performed an in vitro calpain-cleavage assay to test whether calpains are directly involved in Ambra1 proteolysis. To this end, in vitro translated 35 S-labelled Ambra1 was subjected to cleavage by recombinant active calpain-I and -II. As shown in Figure 5d , Ambra1 was completely degraded by both calpains, indicating that calpains are able to directly target Ambra1 and suggesting that they may be responsible for its complete loss during apoptosis. In line with this result, D482A mutation does not interfere with the calpain-dependent cleavage of Ambra1 (Figure 5e ).
To verify that TESD 482 G sequence in Ambra1 is the target for caspase cleavage in cells committed to die, we stably expressed Ambra1
WT and Ambra1 D482A mutant in 2F cells. No detectable cleavage products of Ambra1 D482A mutant were observed when cells were incubated with staurosporine, confirming that this sequence is responsible for Ambra1 cleavage ( Figures 6a and b) ; likewise no alternative cleavages seemed to occur in vivo when this site was mutated. To exclude that the lack of cleavage was due to a misplacement of the mutant Ambra1, we also verify that Ambra1 WT and Ambra1 D482A display a similar subcellular distribution (Supplementary Figure S3c) . Figure 5 Ambra1 is a caspase and calpain substrate. Radioactively labeled recombinant Ambra1-WT (a) or Ambra1-D482A mutant (b) was subjected to an in vitro caspase-cleavage assay by using recombinant active caspase-3, -6, -7 or -8. Samples were subjected to SDS-PAGE and protein fragments visualized by autoradiography. (c) Caspase-3 cleavage of radioactively labelled recombinant Ambra1-WT and Ambra1-D482A mutant. (* points to Ambra1-D482A mutant protein fragment with apparent slightly different molecular weights compared with wild-type protein, likely due to alternative cleavage). (d) Radioactively labeled recombinant Ambra1 was subjected to an in vitro calpain-cleavage assay by using recombinant active calpain-I and -II. Samples were subjected to SDS-PAGE and protein fragments visualized by autoradiography (N ¼ 3) . (e) Radioactively labeled recombinant Ambra1-WT or Ambra1-D482A mutant were subjected to an in vitro calpain-cleavage assay by using recombinant active calpain-I. Samples were subjected to SDS-PAGE and protein fragments visualized by autoradiography (N ¼ 3) As the protein cleavage of other autophagic factors during cell death execution generates protein fragments with proapoptotic function and mitochondrial localization, [14] [15] [16] [17] 26, 27 we transduced 2F cells with retroviral vectors encoding the N-terminal (1-482 aa) and C-terminal (482-1300 aa) Ambra1 fragments and analyzed their activity in relation to apoptosis. We observed that Ambra1 C-terminal fragment has a cellular distribution similar to the full length (WT) (Supplementary Figure S5a and b) and did not modulate the rate of apoptosis when ectopically expressed (Supplementary Figure S5c and  d) . Instead, the Ambra1 N-terminal fragment seems to be highly unstable, since it was undetectable when ectopically expressed (Supplementary Figure S5c) . Collectively, these data suggest that Ambra1 cleavage products, in contrast to other autophagic factors, have no pro-apoptotic functions.
Caspase-uncleavable Ambra1 confers higher resistance to stress-induced cell death. To elucidate whether caspase-mediated degradation of Ambra1 has a role in the execution of apoptosis, Ambra1
WT or Ambra1 D482A mutant was stably expressed in 2F cells (Figure 7a ) and cell death induced by staurosporine or etoposide treatment was evaluated by FACS analysis of sub-G1 DNA content (Figure 7b) . Notably, Ambra1 D482A over-expression was more effective than wild-type Ambra1 in protecting cells against staurosporine-or etoposide-induced apoptosis. The increased protective role of Ambra-D481A to staurosporine treatment was also confirmed by colonyformation assay (Supplementary Figure S3 a and b) .
We then investigated whether the higher pro-survival function of caspase-uncleavable Ambra1 could be attributed to its ability to sustain autophagy for a longer time compared with the WT protein. To this end, we evaluated the autophagy induction in staurosporine-treated cells by measuring the degradation rate of the autophagy reporter p62-GFP. 25 This analysis was preferred to GFP-LC3 dot count because the quantification of the latter was hampered by the significant morphological changes caused by staurosporine. p62-GFPexpressing 2F cells were transduced with b-Gal, Ambra1 WT cells, this correlating with the activation of caspases and cleavage of both endogenous or ectopic Ambra1 (Figures 1a and 2) . By contrast, autophagymediated p62 degradation was still observed in Ambra1 D482A expressing cells after 4 h post treatment, thus correlating with a more efficient apoptosis inhibition of the caspase uncleavable Ambra1 mutant. Indeed, time-course analysis of Ambra1 WT or D482A levels following staurosporine treatment showed that the D 482 -A mutation partially prevents apoptosis-induced Ambra1 decrease (Figure 7d) .
Collectively, these results support for a role of Ambra1 degradation in shutting down the pro-survival functions of autophagy during stress-induced cell death.
Discussion
Under stressful cellular conditions, pro-survival and pro-death processes are concomitantly activated, the final outcome depending on the complex crosstalk between these pathways. 1, 11 The inhibition of autophagy by the apoptotic machinery has been proposed as one of the crucial events responsible for the irreversible switch from survival to death. [14] [15] [16] [17] In the current study, we show that Ambra1 proteolytic degradation during the early phases of apoptosis by caspases and calpains contributes to the abrogation of the pro-survival function of autophagy.
Our findings are consistent with recent studies showing that other autophagic proteins such as Beclin1, Vps34, Atg4D, Atg5 and Vps34 are targets of apoptotic proteases. [14] [15] [16] [17] 26, 27 These data strengthen the emerging view that autophagy impairment by apoptotic machinery could represent a 'point of no return' toward death. However, while protease-mediated cleavage of Beclin1, Atg4D and Atg5 produce truncated proteins acquiring a pro-apoptotic function, [14] [15] [16] [17] 26, 27 Ambra1 cleavage seems to precede a complete protein degradation rather than fragment accumulation. In vitro caspase cleavage assay confirmed that Ambra1 is a substrate of different caspases and allowed us to identify D 482 as a major caspase cleavage site in Ambra1. Significantly, a D 482 -A Ambra1 mutation prevented cleavage product formation in vivo and protected cells from apoptosis more efficiently than the WT protein did. On the other hand, no enhancement of staurosporine-induced apoptosis was observed when caspase-generated Ambra1 fragments were independently expressed in cells (data not shown); this suggests that Ambra1 cleavage products, in contrast to other autophagic factors, have no pro-apoptotic functions. [14] [15] [16] [17] 26, 27 Differently from caspases, calpains completely degrade Ambra1 in an in vitro assay, thus possibly explaining the decrease of Ambra1 protein levels in vivo following apoptosis induction. The fact that Ambra1 decline could be prevented only by concomitant inhibition of calpains and caspases and that a caspase uncleavable Ambra1 mutant is partially resistant to staurosporine-induced degradation seems to confirm that these proteases may function either in concert or independently to ensure Ambra1 removal during apoptosis.
The contribution of Ambra1 degradation to the apoptotic process was confirmed by RNA interference approaches, showing that Ambra1 downregulation markedly sensitized cells to staurosporine-or etoposide-induced cell death. The pro-survival role for Ambra1 was further substantiated by the enhanced resistance to apoptosis of Ambra1 over-expressing cerebellar granule neurons induced to die by trophic factor withdrawal, 21 as well as by the excessive apoptosis observed in selected areas of the developing brain in Ambra1 mutant mice. 19 Apoptosis contributes to the morphogenesis of central nervous system by participating in both the selection of neural precursors and the competition of post-mitotic neurons for their cellular targets. 28 In the light of our results, it would be interesting to analyze whether Ambra1 protein degradation has a functional role in triggering cell death of neuronal cells during embryonic development.
Autophagy impairment has been demonstrated in several neurodegenerative disorders such as in spinocerebellar ataxia and in Parkinson's, Alzheimer's, and Huntington's disease. [29] [30] [31] [32] These pathologies are indeed characterized by intracellular cytotoxic aggregates, calcium imbalance and calpain and caspase activation. Recently, it has also been reported that autophagy inhibition could be due to caspasemediated Beclin1 cleavage in Alzheimer's disease. 26 Sublethal activity of caspase-6 and caspase-7 has also been linked to the onset and progression of Alzheimer and SCA pathologies. 29, 31 Given the functional relationship between Ambra1 levels and caspase activation, an important step forward could be to evaluate the potential value of Ambra1 as a diagnostic or prognostic marker in neurodegenerative disorders and to elucidate the Ambra1 degradation as possible contribution to the onset/progression of these pathologies.
Materials and Methods
Cell culture and treatments. The 2F cell line and Jurkat T cell line were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO, USA) or RPMI-1640 medium, respectively, supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 1% penicillin/ streptomycin solution (Sigma-Aldrich) at 37 1C under 5% CO 2 . Cells were treated with thapsigargin and tunicamycin (Sigma-Aldrich) at a final concentration of 7 mg/ ml, etoposide (Sigma-Aldrich) at 5 mg/ml, staurosporine (Sigma-Aldrich) at 2 mM (or other concentration, when indicated), Fenretinide (Janssen-Cilag Ltd, Basserdorf, Switzerland) at 10 mM, human recombinant TNFa (R&D Systems Inc., Minneapolis, MN, USA) at 10 ng/ml, Rapamycin (Sigma-Aldrich) at 1 mM, as indicated in the figure legends. The above-mentioned agents were added in DMSO with an equal volume of vehicle used to treat control cells (0.1-0.5% DMSO). When indicated, cells were incubated with 10 or 100 mM caspase pan-inhibitor (Z-VAD-fmk; Alexis Biochemicals, San Diego, CA, USA), and 10 or 20 mM calpain pan-inhibitor (CI; N-acetyl-Leu-Leu-Norleu-al; Sigma-Aldrich).
Thymocytes obtained from BALB/CN mice (4-6-week-old) were washed once in RPMI-1640 medium, passed through a nylon mesh, and resuspended in complete medium (RPMI-1640 medium supplemented with 10% heat-inactivated FBS, (Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 1% penicillin/streptomycin solution (Sigma-Aldrich)) at 37 1C under 5% CO 2 . Thymocytes were cultured at 10 6 cells/ml in 24-well plates for either 5 or 6 h in the presence or absence of Dexamethasone (Dex; 1,0 or 0,1 mM; Sigma-Aldrich) or agonistic anti-CD95 Ab (100 ng/ml; ENZO Life Sciences AG, Lausen, Switzerland), respectively.
RNA interference. siRNA oligoribonucleotides corresponding to the human Ambra1 cDNA sequences were purchased from Dharmacon (Dharmacon Inc., Lafayette, CO, USA).
Ambra1 siRNA no. qRT-PCR. RNA was extracted by using Trizol reagent (Invitrogen) as indicated by the supplier. cDNA synthesis was generated using a reverse transcription kit (Promega, Madison, WI, USA) according to the manufacturer's recommendations. Quantitative PCR reactions were performed with the LightCycler (Roche, Nutley, NJ, USA) thermocycler, as previously described. 33 Primer sets for all amplicons were designed using the Primer-Express 1.0 software system (Roche):
L34 forward: L34 mRNA level was used as an internal control and results were expressed as previously described. 33 Western blotting. Total proteins were extracted from cells by using the Cell Lytic buffer (Sigma-Aldrich) following addition of protease inhibitors and resolved by electrophoresis through NuPAGE Bis-Tris gel (Invitrogen) and electroblotted onto nitrocellulose (Protran, Schleicher & Schuell, Dassel, Germany) membrane. Blots were incubated with indicated primary antibodies in 5% non-fat dry milk in PBS plus 0.1% Tween20 overnight at 4 1C. Primary antibodies were: rabbit polyclonal anti-myc Tag antibody (1 : 500; Upstate Biotechnology, Lake Placid, NY, USA), goat anti-Beclin1 (1 : 500; BectonDickinson, Mountain View, CA, USA), rabbit anti-Ambra1 (1 : 2000; Strategic Diagnostic Inc. or Covalab, Cambridge, UK), mouse monoclonal anti-Gapdh (1 : 10 6 ; Calbiochem, San Diego, CA, USA), rabbit polyclonal anti-PARP (1 : 1000; Cell Signaling, Danvers, MA, USA), rabbit polyclonal anti-PARP cleaved (1 : 1000; Cell Signaling), mouse monoclonal anti-Flag (1 : 3000; Sigma-Aldrich), rabbit polyclonal anti-Vps34 (1 : 1000; Invitrogen) and mouse monoclonal anti-Atg5
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